Aerpio Presents Full Results From Phase 1b/2a Study Of AKB-9778 For The Treatment Of Diabetic Macular Edema At Association for Research in Vision & Ophthalmology Annual Meeting
5/5/2014 9:54:32 AM
Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced the presentation of the full results of its Phase 1b/2a study of Tie2 activator, AKB-9778, for the treatment of diabetic macular edema (DME) at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) in Orlando, FL. In the study, one month of daily AKB-9778 treatment was well-tolerated, produced clinically meaningful reduction in retinal thickness, with concomitant improvement in visual acuity, in some of the patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by